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Abstract 
Natural killer (NK) cells are lymphocytes capable of killing virus-infected and 
tumor cells while leaving normal tissue unharmed. CD16 is an Fc receptor that allows 
NK cells to perform antibody-dependent cell-mediated cytotoxicity (ADCC) against 
tumor cells. We hypothesize that miRNAs (miRs) have a regulatory role for CD16 
expression in NK cells. We compiled a list of 69 miRs predicted in silico to target CD16 
mRNA. This list was cross-referenced with a gene expression data set of 400 miRs 
measured in peripheral blood (PB) from 4 healthy donors. Of the 69 miRs candidates, 3 
were found to be downregulated in the CD16+ NK cell populations compared to CD16- 
populations. RT-qPCR showed that CD16- human NK cells in PB had approximately 25 
fold higher mir-218 expression than CD16+ populations (p=0.008, n=4). RT-qPCR was 
also used to measure miR-218 expression during NK cell maturation stages 3, 4a, 4b, and 
5 NK cells from 5 donors. The higher expression of miR-218 in stage 4a and 4b 
developing NK cells correlated to their low expression of CD16. Using 293T cells 
infected with miR-218 pCDH luciferase construct, we were able to demonstrate a 35% 
reduction (p=0.12, n=3) in luciferase activity with overexpression of miR-218. Thus, we 
have preliminary evidence that miR-218 is an intrinsic negative regulator of CD16 
expression in NK cells. Ongoing work will determine the effect of overexpression and 
knockdown of miR-218 on CD16 expression, ADCC killing, and cytokine production in 
a CD16+ cell line and primary NK cells. 
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Introduction 
 Natural killer cells are large granular lymphocytes capable of killing target tumor 
cells and leaving normal tissue unharmed.1 CD16 is an Fc receptor that allows NK cells 
to perform antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells.2-3 
Currently, no factors—transcription factors, epigenetic factors, or microRNAs (miRs)—
have been shown to regulate CD16 expression in NK cells. An understanding of CD16 
regulation in NK cells is required to increased the availability of CD16+ NK cells and 
enhance NK cell-mediated ADCC. Thus, we propose that a better understanding of 
regulatory mechanisms behind CD16 expression in human NK cells will allow for 
improvement in monoclonal antibody immune therapies.  
 The purpose of this research project is to identify and validate miR regulators of 
CD16 in NK cells. Five stages of NK cell development have been identified in the 
secondary lymphoid tissue.4 Stages 1-3 are classified as immature NK cells while stages 
4 and 5 are considered mature NK cells.5 Several markers are used to distinguish NK cell 
stages (see Table 1). Stage 4 NK cells 
lack CD16 expression, while stage 5 
NK cells acquire and highly express 
CD16. To date, little is known about 
the mechanism of transition from stage 4 NK cells to stage 5 NK cells. This research 
project aims to understand how CD16 is expressed and regulated in mature NK cells. We 
hypothesize that the miRs, identified in the preliminary studies, intrinsically regulate 
CD16 in NK cells.  
 
Table	  1:	  Minimal	  Definition	  of	  NK	  cell	  
Development	  
Stage	  3:	  CD34+,	  CD117-­‐,	  CD94-­‐,	  CD16-­‐	  
Stage	  4a:	  CD94+,	  CD34-­‐,	  CD117-­‐,	  NKp80-­‐,	  CD16-­‐	  
Stage	  4b:	  CD94+,	  NKp80+,	  CD34-­‐,	  CD117-­‐,	  CD16-­‐	  
Stage	  5:	  CD94+/-­‐,	  NKp80+,	  CD16+,	  CD34-­‐,	  CD117-­‐	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Figure	   1:	   Peripheral	   blood	   was	   collected	   from	   four	   healthy	  human	   donors	   and	   three	   populations	   were	   sorted:	   CD56bright	  and	  CD56dim,	  which	  are	  abbreviated	  bright	  and	  dim.	  MicroRNA	  expression	  was	  measured	  by	  nanostring	  gene	  expression	  assay.	  Fold	   change	   is	   reported	   as	   a	   ratio	   of	   miR	   expression	   in	   the	  CD56bright	   population	   compared	   to	   the	   corresponding	   CD56dim	  population.	  
Preliminary Studies 
Utilizing the miR prediction strategy 
described in Witkos et al6, we compiled 
a list of 69 miRs predicted in silico to 
target CD16 mRNA. This list was cross-
referenced with a nanostring data set  
 of 800 miRs measured in peripheral 
blood (PB) from 4 healthy donors. The 
first population, CD56bright/CD94high, 
lacks or has low expression of CD16, 
while the two other populations, CD56dim/CD94high and CD56dim/CD94low, highly express 
CD16. Of the 69 miR candidates, 3 were found to be up-regulated in the stage 4 population 
compared to the stage 5 populations in all donor samples (Figure 1).  
NK cell development has traditionally been described as having 5 developmental 
stages, which can be found in the secondary lymphoid tissue (SLT), such as the tonsil. 
However, recent research has attempted to clarify subtle differences in NK cell 
developmental progression by defining stages 4a, 4b, 5a, and 5b.4 Stage 4a NK cells can 
Figure	  2:	  Tonsil	  tissue	  was	  collected	  from	  four	  healthy	  human	  donors	  and	  three	  populations	  were	  sorted:	  Stage	  3,	  4A,	  4B,	  and	  5	  NK	  
cells.	   MicroRNA	   expression	   was	   measured	   by	   qPCR.	   Fold	   change	   is	   reported	   as	   a	   ratio	   of	   miRNA	   expression	   in	   the	   CD56bright	  
population	  compared	  to	  the	  internal	  control.	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Figure	  2a:	  miRNA-­‐92a	  in	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Figure	  2b:	  miRNA-­‐133a	  in	  
tonsil	  NKDI	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  2c:	  miRNA-­‐218	  in	  
tonsil	  NKDI	  
0	  0.5	  
1	  1.5	  
Fo
ld
	  C
ha
ng
e	  
hsa-­‐miR-­‐218	  	  	  hsa-­‐miR-­‐92a	  	  	  hsa-­‐miR-­‐133a
	  	  
Figure	  1:	  miRNA	  over-­‐expressed	  in	  
CD56bright	  	  
Dim	  
Bright	  
Mary Nemer 
 5	  
revert to stage 3, while 4b are committed as mature NK cells (unpublished). Stage 5a are less 
mature than stage 5b NK cells.7 MicroRNA expression in tonsil stage 3, 4a, 4b, and 5 NK 
cells from 5 donors was measured by qPCR (Figure 2). The higher expression of miR in 
stage 4a and 4b NK cells correlates to a low expression of CD16 in stage 4 NK cells. Thus, 
this data suggests that miR serves as a possible regulatory repressor of CD16 in mature 
human NK cells. This proposed research project will further investigate the expression of 
these identified miRs in human CD16+ and CD16- NK cells to validate these preliminary 
findings found via nanostring in PB and qPCR in tonsil.  
 
Research Methodology  
To validate the preliminary nanostring data found in PB, expression of the 3 
identified miRs were measured by qPCR in human CD16+ and CD16- NK cells from PB. 
After validation, we confirmed that miR targets the binding site, which is the 3’ 
untranslated region (UTR) of CD16. This purpose was achieved via luciferase assay of 
transfected human NK-like cell line 293T with identified miRs from the preliminary data. 
First, we cloned the 3’ UTR of CD16 mRNA and miR candidates to create two plasmids: 
a luciferase vector containing the CD16 3’UTR immediately after the luciferase gene and 
an expression vector that was empty or contained the candidate miR. These plasmids 
were used to transfect the 293T cell line creating a miR condition and a control. After 
transfection, the 293T cells were lysed and utilized in the luciferase assay to determine if 
the candidate miR targets the 3’ UTR of the CD16 gene. The luciferase assay quantifies 
the extent to which miR reduces mRNA available for translation. The amount of CD16 
expression with miR present was compared to CD16 expression in the control (empty 
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expression vector which does not contain the miR sequence). The expected outcome was 
to see a decrease in luciferase activity.  
 
Results 
We cloned the 3’ UTR of CD16 mRNA and miR candidates to create two 
plasmids: a luciferase vector containing the CD16 3’UTR immediately after the 
luciferase gene and an expression vector which was empty or contained the candidate 
miRs: mir-92a, mir-133a or mir-218. These plasmids were used to transfect the 293T cell 
line creating a miR condition and a control. After transfection, the 293T cells were lysed 
and utilized in the luciferase assay to determine if the candidate miR targets the 3’ UTR 
of the CD16 gene. The luciferase assay quantifies the extent to which miR reduces 
mRNA available for translation. The amount of CD16 expression with miR present was 
compared to CD16 expression in the control. We were able to demonstrate a 35% 
reduction (p=0.12, n=3) in luciferase activity with overexpression of miR-218 (Figure 3).  
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Figure	  3:	  miR	  regulaNon	  of	  FCGR3A	  3'UTR	  
Figure	  3:	  Confirmation	  that	  miR	  targets	  the	  3’	  untranslated	  region	  
(UTR)	  of	  CD16	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Conclusion 
Human CD16+ natural killer cells are important mediators of ADCC. A better 
understanding of CD16 regulation in NK cells will create opportunities to improve anti-
tumor antibody therapies. Increased surface expression of CD16 in mature human NK 
cells will offer greater potential to engage in ADCC to kill target tumor cells. Through 
this research project we obtained preliminary evidence that miR-218 is an intrinsic 
negative regulator of CD16 expression in NK cells. Ongoing work will determine the 
effect of overexpression and knockdown of miR-218 on CD16 expression, ADCC killing, 
and cytokine production in a CD16+ cell line and primary NK cells. Overexpression of 
miR-218 would be expected to decrease CD16 expression, while knockdown of mir-218 
would be expected to increase CD16 expression. Additionally, to determine the 
developmental role of mir-218, stage 1 CD34+ pro-NK cells will be expanded and 
differentiated in an established NK cell expansion assay system. These future directions 
will help identify specific miRNA pathways that can be exploited to increase NK cell-
mediated ADCC.  
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